<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01570530</url>
  </required_header>
  <id_info>
    <org_study_id>PROFACE</org_study_id>
    <nct_id>NCT01570530</nct_id>
  </id_info>
  <brief_title>Atorvastatin Using as a Possible Prophylaxis of Postoperative Atrial Fibrillation After Cardiac Surgery</brief_title>
  <acronym>PROFACE</acronym>
  <official_title>Atorvastatin Using as a Possible Prophylaxis of Postoperative Atrial Fibrillation After Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación General Universidad de Valladolid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación General Universidad de Valladolid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of atorvastatin therapy (both&#xD;
      during preoperative and postoperative period), as prophylaxis against postoperative atrial&#xD;
      fibrillation after cardiac surgery, in a valve disease patient population (with or without&#xD;
      associated coronary artery disease), with no previous history of atrial fibrillation and not&#xD;
      receiving beta-blocking drugs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    End of finantial support&#xD;
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with postoperative atrial fibrillation(atorvastatin and control groups)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 days.</time_frame>
    <description>To evaluate the effectiveness of atorvastatin therapy (both during preoperative and postoperative period), as prophylaxis against postoperative atrial fibrillation after cardiac surgery, in a valve disease patient population (with or without associated coronary artery disease), with no previous history of atrial fibrillation and not receiving beta-blocking drugs or statins.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory markers values during extracorporeal circulation, and postoperative atrial fibrillation.</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in biochemical markers in both groups.</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in echocardiographic parameters in both groups.</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, duration, characteristics and risk factors for postoperative atrial fibrillation in patients with valve disease (without history of previous arrhythmia) undergoing cardiac surgery.</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and hemodynamic consequences of postoperative atrial fibrillation after cardiac surgery.</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolongation of in-hospital and Intensive Care Unit (ICU) stay and the need for new drug or interventionism therapies, directly related to its appearance.</measure>
    <time_frame>Participants will be followed for the duration of hospital day, an expected average of 10 days.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with atorvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without Atorvastatin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients treated without atorvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac surgery</intervention_name>
    <description>Atorvastatin therapy as prophylaxis against postoperative atrial fibrillation after cardiac surgery</description>
    <arm_group_label>Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac surgery</intervention_name>
    <description>Without atorvastatin therapy as prophylaxis against postoperative atrial fibrillation after cardiac surgery</description>
    <arm_group_label>Without Atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women over 18 year-old.&#xD;
&#xD;
          2. In sinus rhythm.&#xD;
&#xD;
          3. Affected by valve disease, isolated or associated with coronary artery disease,&#xD;
             satisfying requirements for heart surgery under extracorporeal circulation.&#xD;
&#xD;
          4. Women of childbearing potential must use effective contraception and they must commit&#xD;
             to maintain it throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Urgent surgery.&#xD;
&#xD;
          2. Surgery due to endocarditis.&#xD;
&#xD;
          3. Patients with previous episodes of atrial fibrillation, although they are in sinus&#xD;
             rhythm at hospital admission.&#xD;
&#xD;
          4. Treatment with beta-blockers at time of randomization&#xD;
&#xD;
          5. Severe left ventricular dysfunction with ventricular ejection fraction under 30%.&#xD;
&#xD;
          6. Chronic using of NSAIDs and / or corticosteroids at time of randomization&#xD;
&#xD;
          7. Uncontrolled thyroid disease.&#xD;
&#xD;
          8. Active liver disease and / or history of previous chronic liver disease.&#xD;
&#xD;
          9. Alcoholism.&#xD;
&#xD;
         10. Predisposing factors to statins adverse effects:&#xD;
&#xD;
               -  Increased transaminase levels at baseline (x3 normal value).&#xD;
&#xD;
               -  Renal failure (creatinine levels over 2 mg/dl).&#xD;
&#xD;
               -  Previous diagnosis of myopathy of any etiology.&#xD;
&#xD;
         11. Known hypersensitivity to calcium atorvastatin and / or lactose monohydrate&#xD;
&#xD;
         12. In women of childbearing age, positive pregnancy test the day of inclusion in the&#xD;
             study.&#xD;
&#xD;
         13. Not signed informed consent.&#xD;
&#xD;
         14. Inability to understand objectives of the study.&#xD;
&#xD;
        Exclusion criteria of the study once started:&#xD;
&#xD;
          -  Withdrawal of patient's consent.&#xD;
&#xD;
          -  Modification in liver laboratory parameters (transaminases above three times normal&#xD;
             value) and / or creatine-fosfokinase level suggesting adverse effects of statins.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yolanda Carrascal Hinojal, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario de Valladolid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>March 1, 2012</study_first_submitted>
  <study_first_submitted_qc>April 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2012</study_first_posted>
  <last_update_submitted>September 15, 2014</last_update_submitted>
  <last_update_submitted_qc>September 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

